Assessing Organon after a sharp recent move

Organon (OGN) has drawn attention after a sharp share price move over the past month, prompting investors to look more closely at its women’s health focused business, recent financial metrics, and current valuation signals.

The recent sharp move sits on top of an 85.22% year to date share price return and a 54.56% one year total shareholder return, while the three year total shareholder return of 28.34% decline shows that momentum is a recent shift rather than a long term trend.

If Organon’s swing has you rethinking your watchlist, it could be a useful moment to see what else is moving in healthcare by scanning 32 healthcare AI stocks

With Organon trading at a sharp intrinsic discount signal and a recent surge already on the board, the key question is whether the stock still trades below its fundamentals or if the market is already pricing in future growth.

Most Popular Narrative: 19.2% Overvalued

Analyst consensus puts Organon’s fair value at $11.25, which sits below the last close of $13.41 and frames the recent rally as richer than the narrative implies.

The analysts have a consensus price target of $11.25 for Organon based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $14.0, and the most bearish reporting a price target of just $8.0.

Want to see why a higher earnings margin, steady revenue base, and a compressed future P/E are central to this fair value story? The full narrative lays out how these moving parts fit together and what kind of earnings profile they imply several years from now, without assuming tech style multiples.

Result: Fair Value of $11.25 (OVERVALUED)

However, there are still clear risks, including pressure on mature, off patent products and ongoing restructuring costs that could challenge the earnings and margin story.

Another angle on valuation

The analyst target suggests Organon is 19.2% overvalued at $13.41, but the SWS DCF model points the other way, with an estimated future cash flow value of $86.54 per share, or about 84.5% above the current price. Which signal would you lean on when the gap is this wide?

Next Steps

With the signals pointing in different directions, the real question is how you interpret the balance of concerns and potential upside for Organon. Move quickly and test the assumptions against your own expectations using 3 key rewards and 4 important warning signs

Looking for more investment ideas?

If Organon is already on your radar, do not stop there. Broaden your opportunity set and pressure test your thesis against other stocks that fit clear financial filters.

• Target potential upside by scanning companies that screen as 44 high quality undervalued stocks and see which ones line up with your own expectations.
• Focus on resilience by checking out 74 resilient stocks with low risk scores so you can compare Organon with stocks that score well on risk measures.
• Hunt for future standouts by reviewing the screener containing 23 high quality undiscovered gems and see which lesser known stocks deserve a closer look.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.